In a recent study, rivaroxaban was not superior to aspirin for secondary prevention of stroke and systemic emboli after an initial embolic stroke of undetermined source (ESUS) but was associated with a higher risk of bleeding. What does that mean for the concept of ESUS and for future trials?
